Vir(VIR) - 2024 Q3 - Quarterly Results

Exhibit 99.1 Vir Biotechnology Reports Third Quarter 2024 Financial Results and Provides Corporate Update – Successful closing of exclusive worldwide licensing agreement with Sanofi for three potential best-in-class clinical-stage dual-masked T-cell engagers with initial clinical data anticipated in Q1 2025 – – Key Phase 2 SOLSTICE data in chronic hepatitis delta to be presented at AASLD 2024 – – The Company will host a Hepatitis Investor Event following AASLD on November 19, 2024 – – Jason O'Byrne appointe ...